Conavi Medical Shareholders Back Board, Auditor and Expanded Equity Incentive Plan

An announcement from Conavi Medical ( (TSE:CNVI) ) is now available.

Conavi Medical reported the results of its annual general meeting, where shareholders representing just over half of the company’s outstanding common shares participated and elected all seven director nominees with strong support. Shareholders also approved the reappointment of PricewaterhouseCoopers LLP as auditor, reinforcing continuity in financial oversight.

Investors backed amendments to the Omnibus Equity Incentive Plan, increasing the pool of shares available for equity awards to reflect the company’s larger capitalization after recent public offerings and to enhance its ability to attract and retain key talent. Shareholders further approved amendments to stock options held by the former CFO to extend vesting and exercise periods, while both the plan changes and option amendments remain subject to TSXV approval before any affected options can be exercised.

The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.

More about Conavi Medical

Conavi Medical Corp. is a commercial-stage medical device company specializing in imaging technologies that guide minimally invasive cardiovascular procedures. Its flagship Novasight Hybrid System, which combines intravascular ultrasound and optical coherence tomography for simultaneous coronary artery imaging, has received regulatory clearance in the U.S., Canada, China and Japan, supporting its global cardiology market focus.

Average Trading Volume: 53,643

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$32.7M

For detailed information about CNVI stock, go to TipRanks’ Stock Analysis page.